• News
  • SAN DIEGO
  • BioTech

Adamis appoints new board members

San Diego's Adamis Pharmaceuticals Corp. (Nasdaq: ADMP) announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its board of directors. Williams was also appointed as chairman of the board.

Williams has served as the founder and president of Conner-Thoele Limited, a consulting and financial advisory firm specializing in the health care industry and pharmaceutical segment, since 1989. He has completed in excess of 50 divestments, acquisitions, financings and cross-border transactions, which have exceeded $8 billion.

Prior to founding Conner-Thoele, Williams served in a number of operational and financial management positions with multinational firms, including American Hospital Supply Corp., UNC Resources, Abbott Laboratories, Field Enterprises and Erbamont NV.

Williams received a bachelor's degree in economics from DePauw University and a Master of Business Administration from the Wharton School of Finance.

Rothermel is a partner with private investment and management firm CroBern Management Partnership, which works exclusively within the health care industry. Currently, he serves as a board member and chairman of the audit committee of Medcor and has also served as a board member of Cerescan, a private brain imaging company. Prior to CroBern, Rothermel spent 37 years with Deloitte & Touche, and served as a partner and global managing director of the Enterprise Risk Services practice. He also served as a member of Deloitte & Touche's board of directors, the firm's Global Assurance and Advisory Management Committee, the U.S. Management Committee and chaired the firm's Partner Compensation Committee.

Rothermel has a bachelo's degree in business administration from Bowling Green State University.

Denby was senior vice president of commercial operations at Santarus Inc., which was acquired by Salix in January 2014. While at Santarus from 2002-2014, he directed all commercial functions including sales, marketing, market research, customer service, managed care, new product planning and other various functions. Prior to Santarus, he was senior vice president of commercial operations and senior vice president of sales and marketing at Agouron Pharmaceuticals Inc.

Denby has a bachelor of arts degree in English and business from State University of New York at Fredonia and a Master of Business Administration from Rockhurst College.

These three new independent board members have replaced Tina S. Nova, Ph.D., Craig A. Johnson and Kenneth M. Cohen, who submitted written resignations on Aug. 25 after company CEO Dennis J. Carlo on Aug. 22 requested they resign from the board and from all committees. The letter also stated that without the knowledge of the resigning directors and without the participation of the board’s nominating and corporate governance committee (of which the resigning directors constituted all of the members), the CEO had already identified directors to fill the vacancies created by the resigning directors.

User Response
0 UserComments

Adamis Pharmaceuticals Corp.

Company Website

11455 El Camino Real
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ADMP
3.96
  0.09  
+ 2.33%
11,339,000
7.26
3.05

Adamis Pharmaceuticals Corp. Executive(s):

Dennis Carlo

  • Chief Executive Officer, President

Robert Hopkins

  • Chief Financial Officer

Related Articles

Similar Companies

NAICS - 325620 - Toilet Preparation Manufacturing
NAICS - 339112 - Surgical and Medical Instrument Manufacturing